Zynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation Device
(RTTNews) - Medical technology company Zynex, Inc. (ZYXI) announced Tuesday that it has received clearance from the U.S. Food and Drug Administration for the next generation M-Wave Neuromuscular Electrical Stimulation or NMES device.
NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
The M-Wave is designed to improve the way patients manage their neuromuscular conditions. With advanced features and a user-friendly design, the M-Wave allows patients to be treated quickly in a clinical or home setting.
The compact and lightweight design of the M-Wave ensures portability and easy integration into patients' recovery routines.
FTSE 100 Weak Again, Looks Headed For Weekly Loss
Pound Falls Against Majors
French Stocks Mostly Subdued In Cautious Trade
French Inflation Cools; Economy Expands As Estimated
Sensex, Nifty Extend Losses On Trade Worries
DAX Down Nearly 0.5% As Investors Focus On Economic Data
European Shares Drift Lower Ahead Of US Inflation Reading
